

PSP Projects BUY

Order Inflow is the key

Summary

PSP Projects Ltd (PSP) Q3FY22 EBITDA was in-line with our and consensus estimate. Though revenue was lower than our estimate but EBITDA margin was one the highest at 15.3%. EBITDA margin was supported by associated revenue from the completion of project. For FY22/23E company has maintained margin guidance at 12-13%. And expect revenue of Rs16-17bn for FY22E and post that it to increase by 20-25% YoY. PSP currently trades at its historical avg. valuation. We have revised TP to Rs715 (earlier Rs596, at 10x FY24E EPS) valuing the company at 12x FY24E EPS (which is 20% premium to its averages). Key positives in PSP is its execution ability with stable cash flow, lean balance sheet for growth and high double digit ROE at 20%+. Catalyst for stock is order win, as company has bided for projects of Rs35bn and PSP expect inflow of Rs6-7bn in Q4FY22.

Key Highlights and Investment Rationale

- Q3FY22 snapshot: PSP's revenue increased by 24% YoY at Rs4.9bn with EBITDA margin improved to 15.3% (up 330bps YoY). PAT increased by 68% YoY to Rs469mn and 9MFY22 PAT / EBITDA forms 78% to our FY22E estimate.
- Order book at ~2x FY22E Revenue: Order inflow in 9MFY22 is at Rs9.7bn and PSP has order inflow guidance in FY22E at Rs16-17bn. This implies Q4 inflow at Rs6-7bn. As on 3QFY22, order book at Rs33bn (excl slow moving order) provides revenue visibility. With major order of UP medical college (which contributes 45% to OB) has commenced execution.
- Balance Sheet lean: PSP Balance Sheet has net cash of Rs0.2bn and ~50% of bank limit is utilized. Working capital has increased to 42 days as on 9MFY22 but PSP sees this to tread lower as it debtors to reduce by FY22.

ТР	Rs715
CMP	Rs578
Potential upside/downside	+24%
Previous Rating	BUY

Price Perform			
	-1m	-3m	-12m
Absolute	25.7	9.5	38.8
Rel to Sensex	26.0	15.8	18.0

V/s Consensus								
EPS (Rs)	FY22E	FY23E	FY24E					
IDBI Capital	39	48	60					
Consensus	42.0	49.1	57.2					
% difference	(6)	(3)	7					

Key Stock Data		
Bloomberg/Reuters	PSPPL IN /	PSPP.BO
Sector	Infras	tructure
Shares o/s (mn)		36
Market cap. (Rs mn)		20,806
3-m daily avg Trd valu	ue (Rs mn)	15.3
52-week high / low	Rs5	87 / 394

Shareholding Patte	rn (%)
Promoters	70.2
FII	1.7
DII	3.9
Public	24.2

Sensex / Nifty

Financial snapshot

(Rs mn)

57,277 / 17,110

Year	FY20	FY21	FY22E	FY23E	FY24E
Revenue	14,993	12,409	16,443	19,884	23,965
Change (yoy, %)	44	(17)	33	21	21
EBITDA	1,910	1,348	2,133	2,608	3,178
Change (yoy, %)	28	-29	58	22	22
EBITDA Margin(%)	12.7	10.9	13.0	13.1	13.3
Adj.PAT	1,292	835	1,390	1,712	2,144
EPS (Rs)	35.9	23.2	38.6	47.5	59.6
Change (yoy, %)	43	(35)	66	23	25
PE(x)	16	25	15	12	10
Dividend Yield (%)	2	-	1	1	1
EV/EBITDA (x)	4.5	3.8	3.1	2.5	2.0
RoE (%)	31	17	23	23	23
RoCE (%)	39	22	30	29	29

Source: IDBI Capital Research

Vishal Periwal

vishal.periwal@idbicapital.com +91-22-2217 1814



Conference call takeaways:

- EBITDA margin in Q3FY22 increased to 15% due to booking of revenue related to project completion. Completed 5 projects in 3QFY22. But guidance maintained on EBITDA margin at 12-13% for FY22-23E.
- Revenue guidance for FY22 at Rs16-17bn. For FY23E and beyond, expect revenue to increase by 20-25% pa.
- Order inflow guidance in FY22e at Rs16-17bn and 9MFY22 has received Rs9.7bn implying Q4 inflow expected at Rs6-7bn
- Out of total bank limit of Rs11.5bn, utilized Rs.5.5bn of which Rs0.8bnn is fund base utilization and remaining is as non-fund base utilization. Gross debt is at Rs1.9bn with cash bank balance Rs2.1bn
- Out of Rs40bn order book, 18% is slow moving order. Pandarpur order is Rs1.5bn and PSP has completed Rs0.35bn worth of project. PSP stopped the work due to financial constraint with the client. Bhiwandi order of Rs6bn and not much is initiated in this project
- SDB order is expected to get over in Feb-22. This will enable PSP to qualify to bid for project of Rs20bn.
- PSP has bided for project of Rs35bn: Central Vista Rs12bn, Sports complex in Ahmedabad Rs6bn, Residential project in Mumbai Rs3bn, Corporate head office in Ahmedabad Rs2bn, Pharma company project of Rs2bn, Factory project in Surat Rs1.5bn, Steel plant expansion of Rs1.5bn, Phase 2 project of existing client of Rs1bn, Gujarat project of Rs1bn, Temple project of Rs0.8bn.
- For future opportunity, Government has plan to build Vishwanath Project across India which will provide future bid pipeline to PSP. In Central Vista complex, Rs150bn worth of orders is yet to be bided, till date Rs50bn worth of project awarded.
- Complete Precast facility is capitalized with gross block of Rs1.09bn incl land of Rs0.9bn. Peak revenue expected at Rs3bn with 1mn sq feet production. Precast is new tech and will benefit the sector as labor availability is going down in the sector.
- In Dec 2021, the company successfully exited investments in US Subsidiary by selling the stake for a consideration of USD 10,000. Divested 100% stake 10,000 shares in US subsidiary.




Exhibit 1: Financial snapshot


(Rs mn)


Particulars	Q3FY22	Q3FY21	YoY Chg (%)	Q2FY22	QoQ Chg (%)
Revenue	4,856	3,902	24	3,904	24
Cost of Sales ex Depreciation	4,116	3,432	20	3,357	23
EBITDA	741	469	58	547	35
Margin %	15.3	12.0		14.0	
Depreciation	94	64	46	70	33
Other Income	76	38	100	46	65
Interest Expensed	98	30	224	38	159
Pre-tax profit	625	385	62	485	29
Tax	156	106	47	120	31
Adjusted net profit	469	279	68	366	28

Source: Company



















(Rs mn)

Financial Summary

Profit & Loss Account

Year-end: March	FY19	FY20	FY21	FY22E	FY23E	FY24E
Net sales	10,440	14,993	12,409	16,443	19,884	23,965
Change (yoy, %)	43	44	(17)	33	21	21
Operating expenses	(8,951)	(13,083)	(11,060)	(14,310)	(17,275)	(20,787)
EBITDA	1,489	1,910	1,348	2,133	2,608	3,178
Change (yoy, %)	47	28	-29	58	22	22
Margin (%)	14.3	12.7	10.9	13.0	13.1	13.3
Depreciation	(242)	(267)	(256)	(334)	(435)	(519)
EBIT	1,247	1,643	1,092	1,799	2,173	2,659
Interest paid	(92)	(146)	(147)	(116)	(85)	(54)
Other income	229	247	169	186	214	278
Pre-tax profit	1,385	1,744	1,087	1,870	2,302	2,884
Tax	(483)	(452)	(279)	(480)	(591)	(740)
Effective tax rate (%)	34.9	25.9	25.7	25.7	25.7	25.7
Minority Interest	-	-	-	-	-	-
Net profit	902	1,292	808	1,390	1,712	2,144
Exceptional items	-	-	(27)	-	-	-
Adjusted net profit	902	1,292	835	1,390	1,712	2,144
Change (yoy, %)	40	43	(35)	66	23	25
EPS	25	36	23	39	48	60
Dividend per sh	5	10	-	4	4	4
Dividend Payout %	20	28	-	10	8	7



Balance Sr		(Rs mn

Year-end: March	FY19	FY20	FY21	FY22E	FY23E	FY24E
Shareholders' funds	3,714	4,571	5,380	6,626	8,194	10,194
Share capital	360	360	360	360	360	360
Reserves & surplus	3,354	4,211	5,020	6,266	7,834	9,834
Total Debt	4	40	28	28	28	28
Other liabilities	-	4	8	8	8	8
Curr Liab & prov	3,587	4,977	4,488	5,484	6,344	7,390
Current liabilities	3,584	4,970	4,478	5,474	6,334	7,380
Provisions	3	7	10	10	10	10
Total liabilities	3,591	5,022	4,524	5,520	6,380	7,426
Total equity & liabilities	7,305	9,593	9,904	12,146	14,574	17,620
Net fixed assets	1,032	1,079	1,578	1,828	2,093	2,274
Investments	-	-	-	-	-	-
Other non-curr assets	942	1,594	1,414	1,806	2,166	2,587
Current assets	5,332	6,920	6,911	8,512	10,315	12,759
Inventories	750	968	892	1,326	1,604	1,933
Sundry Debtors	1,426	2,240	2,220	2,942	3,558	4,288
Cash and Bank	2,217	1,967	2,288	2,392	2,992	4,009
Loans and advances	158	119	85	111	133	161
Total assets	7,305	9,593	9,904	12,146	14,574	17,620



Cash Flow Statement						(Rs mn)
Year-end: March	FY19	FY20	FY21	FY22E	FY23E	FY24E
Pre-tax profit	1,385	1,744	1,087	1,870	2,302	2,884
Depreciation	242	267	256	334	435	519
Tax paid	(477)	(556)	(243)	(504)	(615)	(765)
Chg in working capital	(720)	(1,116)	(362)	(717)	(528)	(628)
Other operating activities	(153)	(149)	(30)	(70)	(129)	(225)
Cash flow from operations (a)	277	190	708	912	1,464	1,786
Capital expenditure	(394)	(331)	(792)	(584)	(700)	(700)
Chg in investments	(160)	(2)	678	-	-	-
Other investing activities	215	220	168	186	214	278
Cash flow from investing (b)	(339)	(112)	54	(397)	(486)	(422)
Equity raised/(repaid)	-	-	-	-	-	-
Debt raised/(repaid)	2	418	(21)	(266)	(235)	(204)
Dividend (incl. tax)	(217)	(434)	-	(144)	(144)	(144)
Chg in monorities	-	-	-	-	-	-
Other financing activities	-	-	-	-	-	-
Cash flow from financing (c)	(215)	(16)	(21)	(410)	(379)	(348)
Net chg in cash (a+b+c)	(277)	61	741	104	600	1,017



Financial Ratios

Year-end: March	FY19	FY20	FY21	FY22E	FY23E	FY24E
Book Value (Rs)	103	127	149	184	228	283
Adj EPS (Rs)	25.1	35.9	23.2	38.6	47.5	59.6
Adj EPS growth (%)	40	43	-35	66	23	25
EBITDA margin (%)	14.3	12.7	10.9	13.0	13.1	13.3
Pre-tax margin (%)	13	12	9	11	12	12
Net Debt/Equity (x)	-0.6	-0.4	-0.4	-0.4	-0.4	-0.4
ROCE (%)	37	39	22	30	29	29
ROE (%)	27	31	17	23	23	23
DuPont Analysis						
Asset turnover (x)	1.6	1.8	1.3	1.5	1.5	1.5
Leverage factor (x)	1.9	2.0	2.0	1.8	1.8	1.8
Net margin (%)	8.6	8.6	6.7	8.5	8.6	8.9
Working Capital & Liquidity ratio						
Inventory days	26	24	26	29	29	29
Receivable days	50	55	65	65	65	65
Payable days	65	60	86	86	86	86

Valuations

Year-end: March	FY19	FY20	FY21	FY22	FY23E	FY24E
PER (x)	23	16	25	15	12	10
Price/Book value (x)	5.6	4.5	3.8	3.1	2.5	2.0
EV/Net sales (x)	2	1	1	1	1	1
EV/EBITDA (x)	12	10	14	9	7	5
Dividend Yield (%)	1	2	0	1	1	1

Source: Company; IDBI Capital Research





Dealing (91-22) 6836 1111 dealing@idbicapital.com

Key to Ratings Stocks:

BUY: 15%+; **HOLD:** -5% to 15%; **SELL:** -5% and below.

IDBI Capital Markets & Securities Ltd.

Equity Research Desk

6th Floor, IDBI Tower, WTC Complex, Cuffe Parade, Colaba, Mumbai – 400 005. Phones: (91-22) 2217 1700; Fax: (91-22) 2215 1787; Email: info@idbicapital.com

SEBI Registration: BSE & NSE (Cash & FO) - INZ000007237, NSDL - IN-DP-NSDL-12-96, Research - INH000002459, CIN - U65990MH1993GOI075578

Compliance Officer: Christina D'souza; Email: compliance@idbicapital.com; Telephone: (91-22) 2217 1907

Disclaimer

This report has been published by IDBI Capital Markets & Securities Ltd.(hereinafter referred to as "IDBI Capital") for private circulation. This report should not be reproduced or copied or made available to others. No person associated with IDBI Capital is obligated to call or initiate contact with you for the purposes of elaborating or following up on the information contained in this report. The information contained herein is strictly confidential and meant for solely for the selected recipient and may not be altered in any way, transmitted to copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without the prior written consent of IDBI Capital.

Recipients may not receive this report at the same time as other recipients. IDBI Capital will not treat recipients as customers by virtue of their receiving this report.

The information contained herein is from the public domain or sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. While reasonable care has been taken to ensure that information given is at the time believed to be fair and correct and opinions based thereupon are reasonable, due to the very nature of research it cannot be warranted or represented that it is accurate or complete and it should not be relied upon as such. In so far as this report includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Opinions expressed are current opinions as of the date appearing on this material only. While we endeavor to update on a reasonable basis, the information discussed in this material, IDBI Capital, its directors, employees are under no obligation to update or keep the information current. Further there may be regulatory, compliance, or other reasons that prevent us from doing so.

Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice.

IDBI Capital, its directors and employees and any person connected with it, will not in any way be responsible for the contents of this report or for any losses, costs, expenses, charges, including notional losses/lost opportunities incurred by a recipient as a result of acting or non-acting on any information/material contained in the report.

This is not an offer to sell or a solicitation to buy any securities or an attempt to influence the opinion or behavior of investors or recipients or provide any investment/tax advice.

This report is for information only and has not been prepared based on specific investment objectives. The securities discussed in this report may not be suitable for all investors. Investors must make their own investment decision based on their own investment objectives, goals and financial position and based on their own analysis.

Trading in stocks, stock derivatives, and other securities is inherently risky and the recipient agrees to assume complete and full responsibility for the outcomes of all trading decisions that the recipient makes, including but not limited to loss of capital.

Opinions, projections and estimates in this report solely constitute the current judgment of the author of this report as of the date of this report and do not in any way reflect the views of IDBI Capital, its directors, officers, or employees.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject IDBI Capital and associates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this report may come are required to inform themselves of and to observe such restriction.

E-mail is not a secure method of communication. IDBI Capital cannot accept responsibility for the accuracy or completeness of any e-mail message or any attachment(s).

This transmission could contain viruses, be corrupted, destroyed, incomplete, intercepted, lost or arrived late. IDBI Capital, its directors or employees or associates accept no liability for any damage caused, directly or indirectly, by this email.



Analyst Disclosures

I, Vishal Periwal, hereby certify that the views expressed in this report accurately reflect my personal views about the subject companies and / or securities. I also certify that no part of our compensation was, is or will be directly or indirectly related to the specific recommendations or views expressed in this report. Principally, I will be responsible for the preparation of this research report and have taken reasonable care to achieve and maintain independence and objectivity in making any recommendations herein.

Other Disclosure

IDBI Capital Markets & Securities Ltd. (herein after referred to as "IDBI Capital") was incorporated in the year 1993 under Companies Act, 1956 and is a wholly owned subsidiary of IDBI Bank Limited. IDBI Capital is one of India's leading securities firm which offers a full suite of products and services to individual, institutional and corporate clients namely Stock broking (Institutional and Retail), Distribution of financial products, Merchant Banking, Corporate Advisory Services, Debt Arranging & Underwriting, Portfolio Manager Services and providing Depository Services. IDBI Capital is a registered trading and clearing member of BSE Ltd. (BSE) and National Stock Exchange of India Limited (NSE). IDBI Capital is also a SEBI registered Merchant Banker, Portfolio Manager and Research Analyst. IDBI Capital is also a SEBI registered depository participant with National Securities Depository Limited (NSDL) and is also a Mutual Fund Advisor registered with Association of Mutual Funds in India (AMFI).

IDBI Capital and its associates IDBI Bank Ltd. (Holding Company), IDBI Intech Ltd. (Fellow Subsidiary), IDBI Asset Management Ltd. (Fellow Subsidiary) and IDBI Trusteeship Services Ltd. (Fellow Subsidiary).

IDBI Group is a full-serviced banking, integrated investment banking, investment management, brokerage and financing group. Details in respect of which are available on www.idbicapital.com IDBI Capital along with its associates are leading underwriter of securities and participants in virtually all securities trading markets in India. We and our associates have investment banking and other business relationships with a significant percentage of the companies covered by our Research Department. Investors should assume that IDBI Capital and/or its associates are seeking or will seek investment banking or other business from the company or companies that are the subject of this material. IDBI Capital generally prohibits its analysts, persons reporting to analysts, persons reporting to analysts, and their dependent family members having a financial conflict of interest in the securities or derivatives of any companies that the analysts cover. Additionally, IDBI Capital generally prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Directors of IDBI Capital enterest in the Companies under recommendation in this report either as Director or shareholder. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This material should not be construed as an offer to sell or the solicitation of an offer to bu

IDBI Capital hereby declares that our activities were neither suspended nor we have materially defaulted with any Stock Exchange authority with whom we are registered in last five years. However SEBI, Exchanges and Depositories have conducted the routine inspection and based on their observations have issued advice letters or levied minor penalty on IDBI Capital for certain operational deviations. We have not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has our certificate of registration been cancelled by SEBI at any point of time. IDBI Capital, its directors or employees or associates, may from time to time, have positions in, or options on, and buy and sell securities referred to herein. IDBI Capital or its associates, during the normal course of business, from time to time, may solicit from or perform investment banking or other services for any company mentioned in this document or their connected persons or be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or their affiliate companies or act as advisor or lender / borrower to such company(ies)/associates companies or have other potential conflict of interest. This report may provide hyperlinks to other websites. Except to the extent to which the report refers to the websites of IDBI Capital, IDBI Capital, IDBI Capital states that it has not reviewed the linked site and takes no responsibility for the content contained in such other websites. Accessing such websites shall be at recipient's own risk. IDBI Capital encourages the practice of giving independent opinion in research report preparation by the analyst and thus strives to minimize the conflict in preparation of research report. Accordingly, neither IDBI Capital nor Research Analyst have any material conflict of interest at the time of publication of this report. We offer our research services to primarily inst